Antibiotic Exposure Concurrently with Anti-PD1 Blockade Therapy Reduces Overall Survival in Patients with Child–Pugh Class A Advanced Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide with a poor prognosis. Treatment with immune checkpoint inhibitors (ICIs) has improved overall survival in patients with HCC. However, not all patients benefit from the treatment. In this study, 59 patients with HCC...
Main Authors: | Kanan Alshammari, Faizah M. Alotaibi, Futoon Alsugheir, Mohammad Aldawoud, Ashwaq Alolayan, Mohammed Ahmad Algarni, Fouad Sabatin, Mohammad F. Mohammad, Abdulaziz Alosaimi, Faisal M. Sanai, Hassan Odah, Ahmed Saleh Alshehri, Omar S. Aldibasi, Samah Alrehaily, Abdullah S. Al Saleh |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-12-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/16/1/133 |
Similar Items
-
CD3ζ as a novel predictive biomarker of PD-1 inhibitor resistance in melanoma
by: Zhuo Zhang, et al.
Published: (2023-12-01) -
Immune checkpoint inhibitors in combination with radiotherapy as salvage treatment for relapsed/refractory classical Hodgkin lymphoma: A retrospective analysis in 12 patients
by: Elisa Lucchini, et al.
Published: (2021-06-01) -
Prior Anti-Angiogenic TKI-Based Treatment as Potential Predisposing Factor to Nivolumab-Mediated Recurrent Thyroid Disorder Adverse Events in mRCC Patients: A Case Series
by: Luigi Liguori, et al.
Published: (2023-11-01) -
Destabilizing the genome as a therapeutic strategy to enhance response to immune checkpoint blockade: a systematic review of clinical trials evidence from solid and hematological tumors
by: Faizah Alotaibi, et al.
Published: (2024-01-01) -
Predictive value of PD-L1 expression in response to immune checkpoint inhibitors for esophageal cancer treatment: A systematic review and meta-analysis
by: Maryam Noori, et al.
Published: (2022-12-01)